Synthetic osteogenic growth peptide promotes differentiation of human bone marrow mesenchymal stem cells to osteoblasts via RhoA/ROCK pathway

• DOI: 10.1007/s11010-011-0938-7
• Publication Date: 2011-07-07T00:58:42Z
• Authors: Zixian Chen; Xiaofeng Wang; Yunchao Shao; Deyuan Shi; Tongyi Chen; Dafu Cui; Xiaoxing Jiang
• Keywords: Adult; Male; 0301 basic medicine; Osteoblasts; Pyridines; Bone Marrow Cells; Cell Differentiation; Mesenchymal Stem Cells; Amides; 3. Good health; Enzyme Activation; Histones; 03 medical and health sciences; Actin Depolymerizing Factors; Osteogenesis; Focal Adhesion Protein-Tyrosine Kinases; Humans; Intercellular Signaling Peptides and Proteins; Phosphorylation; Phosphotyrosine; Cells, Cultured; Cytoskeleton; Signal Transduction

The osteogenic growth peptide (OGP) is a naturally occurring tetradecapeptide that has attracted considerable clinical interest as a bone anabolic agent and hematopoietic stimulator. In vitro studies have demonstrated that OGP directly regulates the bone marrow mesenchymal stem cells' (BMSCs) differentiation into osteoblasts. However, the exact mechanism of this process remains unknown. In the present study, we investigated the role of RhoA/ROCK signaling in differentiation along this lineage using human BMSCs. OGP treatment increased the mRNA level of bone morphogenetic protein-2 and alkaline phosphatase activity after osteogenic induction. Analysis of BMSCs induced in the presence of OGP revealed an increase in RhoA activity, and phosphorylation of FAK and cofilin. The ROCK-specific inhibitors, Y27632, blocked the OGP-induced regulation of BMSC differentiation. Taken together, these data suggest that OGP not only acts on BMSCs to stimulate osteogenic differentiation, but also in a dose-dependent manner, and this effect is mediated via the activation of RhoA/ROCK pathway.